Earnings
Home›Earnings›Results›Lucid Diagnostics reports Q2 revenue growth, Medicare…
Lucid Diagnostics reports Q2 revenue growth, Medicare LCD timing unchanged
The company said a delayed Medicare draft LCD reflects a CMS bureaucratic backlog, not product-specific issues, and it expects an estimated model to be completed this summer.
Lucid Diagnostics Inc. reported Q2 2026 revenue growth of 17% sequentially, attributing the increase to a shift toward testing opportunities with higher collection probability even as volume stayed flat within its target range of 2,500 to 3,000 tests.
The company said it secured its first Laboratory Benefit Manager coverage policy from Concert, a development management described as validating EsoGuard clinical evidence and establishing medical necessity for at-risk patients. Lucid Diagnostics also noted that the timing of a Medicare draft Local Coverage Determination was delayed due to a broad bureaucratic backlog at CMS, with recent signs that the backlog is loosening.
On commercialization, the company said its VA strategy is moving from clinical engagement to contract securing ahead of the start of the new federal fiscal year on October 1. It also described ongoing health system integration using EHR automated patient identification to streamline candidate selection within large provider groups.
Looking ahead, Lucid Diagnostics said it expects a cost-effectiveness model to be completed this summer to support longer-term economic justification for broader commercial payer adoption, and it remains confident about obtaining a positive Medicare draft LCD, which it estimated would affect 40% to 50% of its addressable patient population. The company added that it expects revenue recognition to shift from a cash collected basis to an accrual basis once predictive data and reimbursement policies become sufficiently stable, and it highlighted projected incremental margins of about 90% for future scaling.